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Abstract Human procarboxypeptidase A2 has been expressed
in a Pichia pastoris heterologous system and purified by
hydrophobic interaction and anion exchange chromatographies.
The hydrolytic action of carboxypeptidase A2 on peptide
substrates with different lengths and residues at the C-terminus
was analysed, and a preference towards long substrates with
aromatic amino acids in their C-terminal end, particularly
tryptophan, was found; with such substrates its activity is similar
or higher than that of bovine carboxypeptidase A1. Procarboxy-
peptidase A2 has been crystallised using a vapour diffusion
approach; the crystals obtained belong to the monoclinic system,
spacegroup P21, and present one procarboxypeptidase A2
molecule per asymmetric unit. The crystals diffract beyond
1.8 Aî resolution and are suitable for detailed X-ray analysis.
z 1997 Federation of European Biochemical Societies.
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1. Introduction
Human procarboxypeptidase A2 (proCPA2) is the inactive
precursor of a pancreatic proteolytic enzyme that belongs to
the family of metallo exoproteases [1]. Human pancreas se-
cretes many of the proteolytic enzymes that participate in the
digestive processes of alimentary proteins and peptides. The
occurrence of these enzymes as inactive (pro) forms, and their
proteolytic maturation upon arrival at their operating zone, is
a control mechanism for the optimum expression of their bio-
logical activity [2,3]. Three forms of monomeric procarboxy-
peptidases, A1, A2 and B occur in human pancreas, together
with a binary complex between the A1 form and proprotei-
nase E [4]. The mature forms of these human procarboxypep-
tidases have a di¡erent role in their functional activity of
removing C-terminal ends of polypeptide chains [4,5] : car-
boxypeptidase B preferentially hydrolyses basic residues, while
carboxypeptidases A1 and A2 have a proteolytic activity on
aliphatic and aromatic or only aromatic side-chain residues,
respectively.
Procarboxypeptidase A2 is an isoform reported until now
only in rat and in humans [4,6,7]. Some structural and func-
tional di¡erences between A1 and A2 isoforms have been
described in the two systems. The A2 isoform shows an acti-
vation mechanism closer to the B form than to the A1 form
[7] ; this is surprising considering the closer homologies to the
latter in sequence and speci¢city. The substrate preference for
A1 and A2 isoforms has been studied in rat; rat CPA1 prefers
smaller amino acids while rat CPA2 prefers bulkier amino
acids [6]. The reports of the crystal structure of rat mature
CPA2 [8] and of several crystal structures of procarboxypep-
tidases [9^11] have allowed a better understanding of the func-
tional di¡erences between these proenzymes based on their
structural determinants. No three-dimensional structure of
human proCPA2 is available until now.
Using a Pichia pastoris heterologous system we have over-
expressed human proCPA2 in the supernatant medium of the
yeast. In this report, we present results concerning the exten-
sive puri¢cation of this proenzyme from the Pichia pastoris
extracellular medium and the systematic enzymatic character-
isation of its mature form with a series of synthetic substrates
that di¡er in length and in C-terminal amino acid. In addi-
tion, the crystallisation and the crystal parameters of the re-
combinant human proCPA2 obtained by X-ray di¡raction
analysis are also reported. The derivation of the three-dimen-
sional structure of this proenzyme could help to clarify the
structural and functional di¡erences between the activation
processes and the substrate speci¢cities for the di¡erent types
of human pancreatic procarboxypeptidases.
2. Materials and methods
2.1. Protein puri¢cation
Human recombinant proCPA2 was secreted at high levels in a
Pichia pastoris heterologous system (Reverter et al., to be published
elsewhere). Puri¢cation from the supernatant was a crucial step due to
non-speci¢c and heterogeneous cleavages at the signal peptide that
produced a di¡erent N-terminus in the recombinant protein. The ¢rst
puri¢cation step was a hydrophobic interaction chromatography: 200
ml of P. pastoris extracellular medium were loaded onto an atmos-
pheric pressure butyl column (butyl 650M Toyopearl, from Tosohaas,
1.5U15 cm) after equilibration with 30% ammonium sulphate. Chro-
matographic elution was performed at 4‡C with a linear gradient of
ammonium sulphate from 30% to 0% in 2 h. The fractions containing
the zymogen were selected by enzymatic activity detection with the
synthetic substrate N-(3-[2-furyl]acryloyl)-L-phenylalanyl-L-phenylala-
nine (FAPP) after activation with trypsin. The protein fraction was
desalted by dialysis against 30 mM MES-acetate (pH 5.7) bu¡er. A
second chromatography in the same bu¡er at pH 5.7 was performed
in an anion exchange preparative column (TSK-DEAE 5PW, from
Toyo-Soda, 2.5U15 cm) connected to an FPLC system (Pharmacia).
A linear smooth salt gradient from 0 M to 0.45 M ammonium acetate
was used to separate the distinct N-terminal processed forms of the
recombinant proCPA2; the chromatography was performed at 22‡C
and the £ow rate kept at 2.5 ml/min. Eluted proteins were kept pre-
cipitated with 45% of ammonium sulphate, at 4‡C, to avoid proteol-
ysis. The nature and purity of the eluted forms of the human proC-
PA2 was con¢rmed by SDS-acrylamide gel electrophoresis, automated
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N-terminal sequence analysis, electrospray mass spectrometry and by
activity measurements with FAPP, as previously described [4].
For crystallisation studies, the puri¢ed protein was immediately
used to avoid autolysis. For kinetic studies, another puri¢cation
step to separate the carboxypeptidase moiety from its pro-segment
was required. The ammonium sulphate precipitate of proCPA2 was
recovered by centrifugation at 13 000 rpm, redissolved in 50 mM Tris-
HCl (pH 8.0) and subsequently desalted on a PD-10 Sephadex G-25M
gel ¢ltration column. The proenzyme was activated by trypsin at 40:1
(w/w) ratio, in 10 min at 25‡C. An anion exchange chromatography
(analytic TSK-DEAE column) in an FPLC system was used to sepa-
rate the tryptic fragments with a linear salt gradient from 5% to 40%
of 0.8 M ammonium acetate. The eluted CPA2 was dissolved at high
salt concentration (0.5 M NaCl) to avoid aggregation.
2.2. Enzymatic assays
Di¡erent synthetic substrates were used to characterise the recombi-
nant puri¢ed human CPA2. The rate of hydrolysis of each substrate
was continuously measured spectrophotometrically in 50 mM Tris-
HCl, 0.5 M NaCl (pH 7.5) at 25‡C. The wavelengths used to monitor
each reaction were as follows: Cbz-Gly-Gly-Phe, Cbz-Gly-Gly-Leu,
Cbz-Gly-Gly-Val, Cbz-Gly-Gly-Ala, Cbz-Gly-Gly-Ser and Cbz-Gly-
Phe, 224^228 nm; Cbz-Gly-Tyr and Cbz-Gly-Gly-Tyr, 236 nm;
Cbz-Gly-Trp and Cbz-Gly-Gly-Trp, 300^304 nm. Initial rates, deter-
mined from the ¢rst 5^10% of each reaction, were obtained at sub-
strate concentrations bracketing the Km value whenever possible. The
kinetic parameters, kcat and Km, were obtained using 6^10 experimen-
tal points by direct ¢t in a Michaelis-Menten curve using the Enz¢tter
program [12].
2.3. Crystallisation and X-ray data collection
The puri¢ed human proCPA2 was concentrated to 12^13 mg/ml
using an Amicon Centriprep 10 concentrator. Protein concentration
was con¢rmed spectrophotometrically and by Bradford Bio-Rad as-
say. Crystallisation was carried out using the hanging drop vapour
di¡usion method at 4‡C and at 20‡C. In a preliminary assay, condi-
tions from the Hampton Crystal Screen I and Crystal Screen II [13]
were carried all out. Crystals were obtained in 20% PEG MME 8000,
0.1 M Tris, pH 8.5, 0.01 M NiCl2 mixing an equal volume of reservoir
solution and protein solution. The pH was screened from 6.0 to 8.5
and the concentration of protein was optimised. The best crystals were
obtained by mixing 5 Wl of protein solution with 1 Wl of reservoir
solution at pH 8.0 and 4‡C.
Crystals were harvested in a solution containing 40% of PEG 8000
MME, 0.1 M Tris, pH 8.0 and mounted in a thin-walled glass capil-
lary tube. Di¡raction analysis was carried out using a Rigaku RU-200
rotating anode generator, KK Cu radiation, and a 300-mm Image
Plate Area Detector from Mar Research. The data were evaluated
with the program DENZO [14].
3. Results and discussion
The optimisation of the puri¢cation method of proCPA2
from the Pichia pastoris supernatant leads to the obtainment
of pure protein through only two chromatographic steps in
two days. The P. pastoris supernatant can be directly loaded
onto a butyl column at atmospheric pressure after equilibra-
tion at 30% saturation with ammonium sulphate. The use of
hydrophobic interaction chromatography avoids the need for
desalting required in other chromatographic variants. The
peak eluted at this step is dialysed against the bu¡er used in
the second chromatographic step, which is performed in an
anion exchange column (TSK-DEAE) due to the negatively
charged character of the proenzyme.
In the selected expression system and conditions, Pichia
pastoris produces several forms of proCPA2 with di¡erent
N-terminal processing and glycosylated variants (Reverter et
al., to be published elsewhere). To solve the problem of het-
erogeneity of proCPA2s it was necessary to investigate high
resolution chromatographic conditions to separate the several
expressed forms. After many trials, we found that the inter-
action of the protein variants with the TSK-DEAE column is
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Fig. 1. Puri¢cation of the correctly and incorrectly processed recombinant forms of human procarboxypeptidase A2. Anion exchange chroma-
tography on a TSK-DEAE column was performed in an FPLC system with a smooth gradient from 30 mM MES-acetic acid, pH 5.7 (solvent
A) to 30 mM MES-acetic acid, 0.45 M ammonium acetate, pH 5.7 (solvent B). The gradient was: 0% solvent B from 0 to 7 min; 5% solvent
B at 15 min; 15% solvent B at 100 min; 100% solvent B at 110 min. Inset: electrophoretic analysis of the peaks of the chromatogram; lanes 1
and 2: I, incorrectly processed proCPA2; lanes 3 and 4: native proCPA2; lanes 5 and 6: I/G, incorrectly processed and glycosylated proCPA2;
lanes 1, 3, 5 and 2, 4, 6 contain samples before and after activation with trypsin, respectively. Lane 7: molecular mass markers. The position
of the activation (pro-) segment of PCPA2 is indicated by asA2.
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weak and slightly di¡erent at pH 6.0, the proteins still being
activatable (the zinc atom is lost at lower pH). The combina-
tion of this pH with a smooth ammonium acetate gradient
allowed the separation of the well-processed N-terminal proC-
PA2 from the other incorrectly processed or glycosylated
forms. A typical pro¢le obtained in the second chromatogra-
phy is displayed in Fig. 1. The main peaks contained di¡erent
forms of proCPA2 as shown by enzymatic measurements,
electrophoretic analysis and N-terminal sequencing, and
each peak generated active carboxypeptidase after activation
with trypsin. The ¢rst and third large peaks were found to
contain incorrectly processed proCPA2s, the latter being a
glycosylated form. The second large peak (eluted at 90 min)
was found to contain native ^ well processed ^ proCPA2, as
con¢rmed by mass spectrometry when its molecular mass was
compared with that derived from gene sequencing [5]. The
puri¢cation of the native proCPA2 was a prerequisite for
the subsequent enzymatic and crystallographic analyses.
Fully active and pure CPA2 was produced by limited pro-
teolysis of any of the above proCPA2 variants with trypsin,
followed by anion exchange chromatography on a TSK-
DEAE column, as described in Section 2. The occurrence of
the di¡erential processing or glycosylation of proCPA2 during
expression at the N-terminus of the pro-region did not prevent
the homogeneous generation of CPA2 by trypsin cleavage at
the boundary between the pro-segment and the active enzyme
moiety.
A functional characterisation of the enzyme was performed
by means of a series of substrates of the type Cbz-(Gly)n-L-X
that di¡ered in their lengths and in their C-terminal amino
acids. In Table 1 the kinetic constants derived for human
CPA2 are compared with those for bovine CPA1, a model
enzyme of type A carboxypeptidases. In the case of shorter
substrates (n = 1), human CPA2 was only able to hydrolyse
those containing a C-terminal aromatic residue, with the ex-
ception of a residual activity detected for the substrate with C-
terminal leucine; no activity was detected with substrates con-
taining other residues at this position, such as alanine, serine,
arginine or lysine. For substrates with two glycine residues,
the higher activity was observed with C-terminal tryptophan
followed by those with tyrosine and phenylalanine, respec-
tively. The kcat/Km values for these longer substrates for hu-
man CPA2 are comparable with those derived for bovine
CPA1 for C-terminal tyrosine, smaller for phenylalanine and
much larger for tryptophan; in the latter case, the activity is
not measurable in bovine CPA1. These results agree with the
hypothesis of a large binding pocket proposed for rat CPA2
that would be able to accommodate the large aromatic sub-
strates better [8]. For short substrates with only one glycyl
residue, there is also a correlation between the activity and
the size of the aromatic C-terminal residue in the substrate,
although the kcat/Km values are lower compared with the sub-
strates with one more glycine. Thus, it seems clear that longer
substrates can be placed better in the binding pocket of the
enzyme, allowing for a better ¢lling of the di¡erent subsites,
as proposed for other carboxypeptidases [1].
The kinetic constants in Table 1 con¢rm the results that
de¢ne the A2 isoform as an enzyme that preferentially cata-
lyses the removal of aromatic and bulkier residues from the C-
terminus of peptides and proteins. In contrast to the A1 iso-
form, CPA2 is the only reported carboxypeptidase with spe-
ci¢city for C-terminal tryptophan residues; this fact increases
the importance of this exoprotease that can be used in con-
trolled digestions removing C-terminal tryptophan ends of
peptides and proteins in vitro or in vivo. It is also worth
mentioning that the proenzyme shows intrinsic (remnant) ac-
tivity against the above mentioned substrates. The percentages
of activity of the proenzyme compared to the active enzyme
against a number of substrates at 1 mM concentration are as
follows: 3% for Cbz-Gly-Trp, 1.5% for Cbz-Gly-Gly-Trp,
10% for Cbz-Gly-Tyr, 5% for Cbz-Gly-Gly-Tyr, and 0.45%
for FAPP. This is an indication that the active site is pre-
formed in the zymogen and that its accessibility is more re-
stricted for longer substrates.
Crystallisation of recombinant proCPA2 was only possible
after an accurate chromatographic puri¢cation of the well-
processed N-terminal proCPA2 in an anion exchange TSK-
DEAE column, performed at low pH and with smooth gra-
dient conditions, as previously described. Repuri¢cation of
the peak under the same chromatographic conditions was
necessary to avoid minor contamination from other variants
that could interfere with the crystallisation of the enzyme. To
avoid autolysis processes in the puri¢ed proCPA2, crystallisa-
tion experiments were started just after the repuri¢cation of
the protein. The proenzyme was concentrated up to 12.5 mg/
ml and dialysed against 2 mM MOPS, pH 7.0 using an Ami-
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Table 1
Kinetic constants for peptide substrate hydrolysis by human CPA2 and bovine CPA1, assayed in aqueous bu¡er (50 mM Tris-HCl, 0.5 M Na
Cl, pH 7.5) at 25‡C
Substrate Human CPA2 Bovine CPA1
Kcat (s31) Km (WM) Kcat/Km
(U1035)
Kcat (s31) Km (WM) Kcat/Km
(U1035)
Cbz-Gly-Gly-Phe 58.3 þ 2.4 372 þ 30 1.57 131.5 þ 3.1a 172 þ 12a 7.62
Cbz-Gly-Gly-Tyr 70.0 þ 5.3 125 þ 15 5.60 56.3 þ 2.0a 102 þ 2a 5.51
Cbz-Gly-Gly-Trp 90.3 þ 7.0 146 þ 9 6.18 NMb NMb
Cbz-Gly-Gly-Leu 11.8 þ 1.1 5300 þ 1400 0.03 63.4 þ 2.5b 1180 þ 93b 0.54
Cbz-Gly-Gly-Val NM NM 19.5 þ 2.0 3720 þ 390 0.52
Cbz-Gly-Gly-Ala NM NM NM NM
Cbz-Gly-Gly-Ser NM NM NM NM
Cbz-Gly-Phe 16.1 þ 1.3 2270 þ 200 0.07 41.7 þ 2.8a 1093 þ 154a 0.38
Cbz-Gly-Tyr 9.7 þ 0.6 175 þ 10 0.56 16.0 þ 0.6a 394 þ 29a 0.41
Cbz-Gly-Trp 33.8 þ 1.1 261 þ 12 1.29 50.0 þ 4.3a 3310 þ 430a 0.15
NM, non-measurable; the extremely low rates of hydrolysis of such substrates did not permit derivation of Michaelis-Menten parameters.
aKinetic values taken from [6].
bKinetic values taken from [15].
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con centriprep 10 concentrator. Large crystals were obtained
using PEG MME as precipitant. After growing during one
week, the crystals achieved a ¢nal size of 1U1U0.6 mm.
The obtainment of well-ordered crystals of proCPA2, suit-
able for X-ray di¡raction analysis, was found to be critically
dependent on an e⁄cient and fast puri¢cation, performed just
before crystallisation. The crystals (Fig. 2) di¡ract beyond 1.8
Aî resolution using a rotating anode X-ray source and are
stable under the X-ray beam. They belong to the monoclinic
space group P21 with unit cell parameters a = 42.2 A, b = 87.1,
c = 59.0 and L= 99.3‡. The Vm value is 2.23 Aî 3/dalton with
one proCPA2 molecule per asymmetric unit. A 1.8 Aî resolu-
tion data set has been collected resulting in 37 420 unique
re£ections at the 2c (F0) level. This data set is 94% complete
(88% complete in the 1.86^1.8 outermost resolution shell). The
overall I/c(I) is 32.6, being 9.1 in the 1.86^1.8 resolution shell.
The determination of the native structure of the proCPA2 will
be performed by means of the molecular replacement method,
using the structure of porcine pancreatic procarboxypeptidase
A1 [10] as initial model.
The resolution of the human proCPA2 structure could clar-
ify the functional and structural di¡erences between procar-
boxypeptidase isoforms and should provide insight into the
inhibition mechanism and trypsin activation process of the
proenzyme, as well as on the substrate preferences through
the study of its speci¢city pocket. It could also be of great
use in the redesign of the speci¢city pocket of the active en-
zyme, a subject of biotechnological interest nowadays [15].
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Fig. 2. Crystal specimen of recombinant human procarboxypepti-
dase A2. The crystals were obtained in 20% PEG and 10 mM
NiCl2, belonged to the monoclynic system, and the largest ones
were of approximate dimensions of 1U1U0.6 mm.
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